RecruitingPhase 4NCT07203287

Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease


Sponsor

The University of Texas Medical Branch, Galveston

Enrollment

490 participants

Start Date

Aug 26, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of the study is to determine which combination of neuromuscular blocking agent and reversal agent is safer to use during anesthesia for patients with chronic kidney disease. The main question it aims to answer is "The use of Cisatracurium with neostigmine leads to less post-operative pulmonary complications than Rocuronium with sugammadex."


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing two different muscle relaxant medications used during surgery — rocuronium and cisatracurium — in patients with chronic kidney disease. Researchers want to find out which medication is safer and causes fewer complications in people with reduced kidney function. **You may be eligible if...** - You are between 18 and 80 years old - You have been diagnosed with chronic kidney disease (based on kidney filtration rate tests) - You are scheduled for surgery that requires general anesthesia with a breathing tube and muscle relaxants **You may NOT be eligible if...** - You are younger than 18 or older than 80 - You have end-stage kidney disease or are on dialysis - You are scheduled for a kidney transplant - You are pregnant - Your surgery is urgent or an emergency - Your surgery will require you to remain on a breathing tube after the operation - You have a known allergy to rocuronium, sugammadex, cisatracurium, or neostigmine - You are currently incarcerated Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRocuronium

Will be assessing neuromuscular blockade with rocuronium and reversal with sugammadex

DRUGCisatracurium

Will be assessing neuromuscular blockade with neostigmine and reversal with neostigmine

DRUGSugammadex

Will be assessing neuromuscular blockade with rocuronium and reversal with sugammadex

DRUGNeostigmine

Will be assessing neuromuscular blockade with neostigmine and reversal with neostigmine


Locations(1)

University of Texas Medical Branch

Galveston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07203287


Related Trials